Cytokinetics, Incorporated (CYTK)

Market Cap	4.38B
Revenue (ttm)	19.22M
Net Income (ttm)	-615.26M
Shares Out	119.43M
EPS (ttm)	-5.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,088,724
Open	37.40
Previous Close	37.64
Day's Range	36.60 - 38.06
52-Week Range	29.31 - 59.81
Beta	0.60
Analysts	Buy
Price Target	70.92 (+93.3%)
Earnings Date	Aug 7, 2025

About BLUE

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Financial numbers in CAD

Analyst Summary

According to 14 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $70.92, which is an increase of 93.30% from the latest price.

Price Target

$70.92

(93.30% upside)

Analyst Consensus: Buy